2-(chloromethyl)oxirane; prop-2-en-1-amine

• ChemBase编号: 540
• 分子式: C6H12ClNO
• 平均质量: 149.61858
• 单一同位素质量: 149.06074169
• SMILES: ClCC1OC1.NCC=C
• Canonical SMILES: ClCC1CO1.C=CCN
• InChI: InChI=1S/C3H5ClO.C3H7N/c4-1-3-2-5-3;1-2-3-4/h3H,1-2H2;2H,1,3-4H2
• InChIKey: ZNSIZMQNQCNRBW-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-(chloromethyl)oxirane; prop-2-en-1-amine
• IUPAC传统名: allylamine; epichlorohydrin
• 商标名: Renagel
• 别名: Sevelamer; 2-Propen-1-amine Hydrochloride polymer with 2-(Chloromethyl)oxirane; 2-Propen-1-amine Hydrochloride polymer with (Chloromethyl)oxirane; (Chloromethyl)oxirane polymer with 2-Propen-1-amine Hydrochloride; Allylamine Hydrochloride-epichlorhydrin Copolymer; Allylamine Hydrochloride-epichlorohydrin Copolymer; GT 16-026A; Phosblock; RenaGel; Sevelamer Hydrochloride

登记号

• CAS号: 152751-57-0
• PubChem SID: 46505951; 160964003
• PubChem CID: 3085017

理论计算性质

• 质子受体: 1
• 质子供体: 0
• LogD (pH = 5.5): 0.6772814
• LogD (pH = 7.4): 0.6772814
• Log P: 0.6772814
• 摩尔折射率: 20.057 cm^3
• 极化性: 8.123073 Å^3
• 极化表面积: 12.53 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Insoluble
• 疏水性(logP): 0.559

详细说明

DrugBank - DB00658

• Drug Groups: approved
• Description: Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.
• Indication: For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
• Pharmacology: Patients with end-stage renal disease (ESRD) retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. When the product of serum calcium and phosphorus concentrations (Ca x P) exceeds 55 mg^2/dL^2, there is an increased risk that ectopic calcification will occur. Hyperphosphatemia plays a role in the development of secondary hyperparathyroidism in renal insufficiency. An increase in parathyroid hormone (PTH) levels is characteristic of patients with chronic renal failure. Increased levels of PTH can lead to osteitis fibrosa, a bone disease. A decrease in serum phosphorus may decrease serum PTH levels. Treatment of hyperphosphatemia includes reduction in dietary intake of phosphate, inhibition of intestinal phosphate absorption with phosphate binders, and removal of phosphate with dialysis. Sevelamer taken with meals has been shown to decrease serum phosphorus concentrations in patients with ESRD who are on hemodialysis. In vitro studies have shown that the capsule and tablet formulations bind phosphate to a similar extent. Sevelamer treatment also results in a lowering of low-density lipoprotein (LDL) and total serum cholesterol levels.
• Toxicity: Sevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.
• Affected Organisms: Humans and other mammals
• Absorption: Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease.
• External Links: Wikipedia; RxList; Drugs.com

Toronto Research Chemicals - S256000

Sevelamer hydrochloride is a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.

参考文献

• Wells, K., et al.: Am. J. Psychiatry, 156, 5 (1999)
• Finn, W., et al.: Clin. Nephrol., 65, 191 (1999)
• Hutchison, A., et al.: Nephrol. Clin. Pract., 102, 61 (1999)